Amyris, Inc. (AMRS)
Stock Price Chart
Key Info
| Market Cap | 635.11M |
| Revenue (ttm) | 133.93M |
| Net Income (ttm) | -352.02M |
| Shares Out | 239.21M |
| EPS (ttm) | -2.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | November 24 |
| Last Price | $2.66 |
| Previous Close | $2.42 |
| Change ($) | 0.24 |
| Change (%) | 9.71% |
| Day's Open | 2.51 |
| Day's Range | 2.46 - 2.70 |
| Day's Volume | 1,796,839 |
| 52-Week Range | 1.40 - 6.07 |
More Stats
| Market Cap | 635.11M |
| Enterprise Value | 792.12M |
| Earnings Date (est) | Mar 3, 2021 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 239.21M |
| Float | 134.53M |
| EPS (basic) | -2.05 |
| EPS (diluted) | -2.04 |
| FCF / Share | -0.98 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 24.72M |
| Short Ratio | 15.41 |
| Short % of Float | 18.37% |
| Beta | 0.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 4.74 |
| PB Ratio | n/a |
| Revenue | 133.93M |
| Operating Income | -152.32M |
| Net Income | -352.02M |
| Free Cash Flow | -222.97M |
| Net Cash | -157.01M |
| Net Cash / Share | -0.66 |
| Gross Margin | 8.89% |
| Operating Margin | -113.73% |
| Profit Margin | -262.80% |
| FCF Margin | -166.48% |
| ROA | -56.92% |
| ROE | n/a |
| ROIC | -96.50% |
Analyst Forecasts
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 153 | 63.60 | 128 | 67.19 | 34.15 | 43.27 | 41.12 | 73.69 | 147 | 80.31 |
| Revenue Growth | 139.85% | -50.18% | 90.01% | 96.74% | -21.08% | 5.24% | -44.2% | -49.86% | 83.03% | - |
| Gross Profit | 76.37 | 26.91 | 65.36 | 10.51 | -3.22 | 10.07 | 2.87 | -3.62 | -8.62 | 9.80 |
| Operating Income | -122 | -137 | -56.05 | -95.92 | -149 | -99.83 | -120 | -202 | -179 | -83.79 |
| Net Income | -243 | -230 | -156 | -97.33 | -218 | 2.29 | -235 | -205 | -179 | -81.87 |
| Shares Outstanding | 101 | 60.41 | 32.25 | 15.90 | 8.46 | 5.23 | 5.03 | 3.78 | 2.99 | 0.99 |
| Earnings Per Share | -2.72 | -3.69 | -6.26 | -6.55 | -26.20 | -13.50 | -46.80 | -54.30 | -59.85 | -125.24 |
| Operating Cash Flow | -157 | -109 | -101 | -82.37 | -85.13 | -84.71 | -106 | -151 | -92.50 | -64.58 |
| Capital Expenditures | -13.08 | -12.47 | -4.41 | -0.92 | -3.37 | -5.00 | -8.09 | -56.86 | -97.02 | -15.51 |
| Free Cash Flow | -170 | -122 | -106 | -83.29 | -88.50 | -89.71 | -114 | -208 | -190 | -80.09 |
| Cash & Equivalents | 0.74 | 46.09 | 60.05 | 32.85 | 14.69 | 45.04 | 9.94 | 31.64 | 104 | 258 |
| Total Debt | 94.24 | 210 | 164 | 227 | 153 | 233 | 153 | 107 | 47.66 | 12.59 |
| Net Cash / Debt | -93.50 | -164 | -104 | -194 | -138 | -188 | -143 | -75.13 | 55.93 | 245 |
| Assets | 161 | 128 | 141 | 130 | 106 | 216 | 199 | 243 | 320 | 357 |
| Liabilities | 411 | 340 | 353 | 308 | 265 | 341 | 335 | 177 | 159 | 49.91 |
| Book Value | -256 | -218 | -218 | -184 | -158 | -124 | -135 | 67.11 | 161 | 308 |
Company Profile
Company Details
| Full Name | Amyris, Inc. |
| Country | United States |
| Employees | 561 |
| CEO | John G. Melo |
Stock Information
| Ticker Symbol | AMRS |
| Stock Exchange | NASDAQ |
| Sector | Basic Materials |
| Industry | Specialty Chemicals |
| Unique Identifier | NASDAQ: AMRS |
| IPO Date | September 28, 2010 |
Description
Amyris, a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. The company's technology platform enables to engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. It applies technology platform to engineer, manufacture, and sell products for the clean health and beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.